OCT 03, 2016 9:23 AM PDT

Metastatic Tumors Outsmart the Immune System

WRITTEN BY: Kara Marker
Why can the immune system recognize and attack primary tumors but not metastatic tumors? Researchers from the University of British Columbia, in collaboration with the Vancouver Prostate Centre, have the answer.
Biopsy of a highly differentiated squamous cell carcinoma of the mouth.
According to results from a study of human cancer patients, some individuals with prostate or renal cancer tumors showed an exceptional loss of an immune protein called interleukin-33 (IL-33). Without IL-33, cancer cells were able to “hide” from the immune system, and these patients were more likely to see their cancer return within five years.

After further investigating the role of IL-33 in immune evasion by cancer cells, researchers saw that effector T lymphocytes responsible for targeting tumors, like cytotoxic T cells, rely on IL-33 as a signal for denoting if a cell is cancerous. "IL-33 could be among the first immune biomarkers for prostate cancer and we are planning to examine this in a larger sample size of patients," said first author Iryna Saranchova.

The loss of IL-33 occurs in epithelial carcinomas, the cancers that initially develop in the lining of organs: prostate, kidney, breast, lung uterine, cervical, pancreatic, skin, and many more. Compared to other interleukins in the same family, IL-33 has unique intracellular and extracellular features. Inside the cell, IL-33 helps maintain barrier function by regulating gene expression, and outside the cell IL-33 is in charge of immune defense and repair mechanisms while simultaneously triggering the differentiation of helper T cells during the adaptive immune response.

IL-33 also works through a protein complex called major histocompatibility complex (MHC) to alert circulating effector T lymphocytes to the presence of a cancer cell. In addition to signaling the presence of cancer, MHC binds peptide fragments derived from pathogens for display on the cell surface so T cells will be aware of a microbial invasion. Even if MHC is present and functioning, without IL-33, the signaling process is ineffective. 

For cancer patients with epithelial carcinomas, monitoring levels of IL-33 could be an effective way to track the progression of their cancer. Additionally, resupplying cancerous cells with IL-33 could help the immune system start to recognize and attack again, according to results from the study. More experiments will be conducted to confirm the efficacy and safety of this treatment in clinical trials.

The present study was recently published in the journal Scientific Reports.
 


Sources: The University of British Columbia, Nature Immunology, Immunobiology: The Immune System in Health and Disease 5th edition, Journal of Cellular Physiology
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
FEB 14, 2020
Immunology
FEB 14, 2020
Rewired natural killer cells show promising results in leukemia patients
Natural killer (NK) cells are a subset of white blood cells that are key players in the innate immune system, orchestrat ...
FEB 19, 2020
Immunology
FEB 19, 2020
Testing the Immune Response to Ovarian Cancer Treatment
There is a new diagnostic test for the deadliest form of gynecological cancer – ovarian cancer. Better tests mean ...
MAR 20, 2020
Drug Discovery & Development
MAR 20, 2020
4 Potential Treatments for SARS-CoV-2 Currently Under Testing
Currently, no medicine nor vaccine has been approved as effective for the prevention of severe acute respiratory syndrom ...
APR 21, 2020
Cancer
APR 21, 2020
Scientists develop tumor immunity map
A new study published in eLife describes the findings from a study that has successfully mapped tumor cell molecule ...
APR 26, 2020
Microbiology
APR 26, 2020
Researchers Design A Polio Vaccine That Won't Cause Polio
Sustained, intense efforts to vaccinate were getting the world very close to eradicating polio, but the vaccine itself o ...
MAY 19, 2020
Drug Discovery & Development
MAY 19, 2020
Can Chinese Drug Cure COVID-19 Without Vaccine?
Researchers at China’s Peking University have announced that they are developing a treatment capable of blocking C ...
Loading Comments...